Posted inMedical Technology
Editor’s corner: Fierce Medtech’s top 10 stories of 2024 chart the industry’s highs and lows
A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment…
Posted inMedical Technology
FDA approves Humacyte’s off-the-shelf artery implant for vascular trauma repair
The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed to replace a…
Posted inBiotechnology
Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis prospect
After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found…
Posted inBiotechnology
Rapt re-rolls after flameout, paying $35M for challenger to Novartis, Roche drug
Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a…
Posted inBiotechnology
Sanofi pays SK bioscience €50M as children’s pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine…
Posted inBiotechnology
Phase 2 data will drive biopharma VC investments next year: PitchBook
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into…
Posted inGenetics
StockWatch: Wall Street’s Leaders and Laggards of 2024
2024 had its dazzling moments, but, in the end, it was a year of treading water for biopharma stocks, judging…
Posted inBiotechnology
Discover Astellas’ differentiated approach to innovation partnerships
As a global life sciences company, Astellas is passionate about partnering to advance life-changing treatments for patients. If you are…
Posted inResearch
Clinical trials industry to grapple with new tech, additional uncertainty in 2025: Velocity Clinical Research CEO
Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies and…
Posted inBiotechnology
Galectin’s MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people…